The Clinical Stream provides grant funding up to $1,500,000 (per project) to support the development of clinical stage drug therapies to treat disease. Clinical Stream projects will have the opportunity to apply for matching (dilutive) investment from Brandon BioCatalyst or third-party funding on an investment for equity basis. Projects are not required to accept matching equity-based funding to receive the grant.
This program, supported by the MRFF Early Stage Translation and Commercialisation Support (ESTAC) grant, is directed towards supporting the design, commencement and/or completion of phase 1 and phase 2 clinical studies, including investigator led and multi-centre studies. Patient studies (phase 1b and 2a and beyond) will be designed to:
• validate safety
• generate evidence of efficacy – using both traditional measures of disease and novel, cutting edge biomarkers and analysis.
Eligible projects include early clinical development of novel drugs, or novel uses for existing drugs with commercial potential. Each project supported by CUREator will need to be carefully designed, with clearly defined project deliverables and early go/no-go milestones to ensure project activity completion within 12-24 months, delivering key value-adding and de-risking milestones during the grant period. Successful applicants must perform the research in Australia (where possible); and funding must be provided to an Australian for-profit company.
Funding guidelines regarding this stream can be found here.
Awardees of the Clinical Stream can be found here for Round 1 and here for Round 2).
